Document is current
Any future updates will be listed below
-
Authors
Hirsch, Annemarie G.
Schwartz, Brian S.
Nordberg, Cara M.
Tan, Bruce K.
Schleimer, Robert P.
Kern, Robert C.
Peters, Anju T.
Bandeen-Roche, Karen
Lehmann, Ashton E.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (PO1AI145818, PO1AI145818, PO1AI145818, PO1AI145818, PO1AI145818, PO1AI145818, PO1AI145818, PO1AI145818, PO1AI145818)
- License Information
-
More Information
Article History
Received: 16 August 2024
Accepted: 12 May 2025
First Online: 20 May 2025
Declarations
:
: Geisinger Institutional Review Board approved this study and approved a waiver of consent. This study adhered to the Declaration of Helsinki.
: Not applicable.
: R. Kern serves as a senior consultant for Lyra Therapeutics and has received consulting fees from Sanofi-Regeneron and GSK. B. Tan has received consulting fees from Sanofi-Regeneron. R.P. Schleimer receives royalties from patents licensed by Johns Hopkins University to Allakos; he has received consulting fees from Intersect ENT, Merck, GSK, Sanofi Regeneron, AstraZeneca/Medimmune, Genentech, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharma, Allakos, and Otsuka; and he owns stock in Allakos. A.T. Peters has received research grants or contracts from Sanofi Regeneron, Optinose, and AstraZeneca and consulting fees from SanofiRegeneron, AstraZeneca, Optinose, and GSK. The remaining authors declare that they have no relevant conflicts of interest.
